Search

Your search keyword '"Yi, Zongbi"' showing total 145 results

Search Constraints

Start Over You searched for: Author "Yi, Zongbi" Remove constraint Author: "Yi, Zongbi"
145 results on '"Yi, Zongbi"'

Search Results

1. CandidateDrug4Cancer: An Open Molecular Graph Learning Benchmark on Drug Discovery for Cancer

6. A lactate‐responsive gene signature predicts the prognosis and immunotherapeutic response of patients with triple‐negative breast cancer.

19. Molecular landscape ofTP53mutations in breast cancer and their utility for predicting the response to HER ‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients

22. Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation‐wide multicenter study

23. Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients.

24. Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer

27. Molecular Landscape of Tp53 Mutations in Breast Cancer and Their Utility for Predicting Response to HER-Targeted Therapy in HER2 Amplification-Positive and HER2 Mutation-Positive Amplification-Negative Patients

28. Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients

33. The prevalence of BRCA1/2 germline mutation in Chinese pan-cancer.

34. Development and validation of a new clinical prediction model of catheter-related thrombosis in cancer patients.

38. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

39. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer

42. Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: A phase I clinical trial.

45. Analysis of circulating tumor DNA to monitor metastatic breast cancer patients treated with first-line chemotherapy (CAMELLIA study).

48. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer.

Catalog

Books, media, physical & digital resources